Loading stock data…
LXRX
$1.63+0.02 (+1.24%)
Market ClosedLast close May 1
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Lexicon Pharmaceuticals, Inc. in the Healthcare sector is trading at $1.63. The stock is currently 16% below its 52-week high of $1.95, remaining 18.1% above its 200-day moving average. Technical signals show neutral RSI of 44 and bearish MACD signal, explaining why LXRX maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 44) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.63
Potential Upside
5%
Whystock Fair Value$1.71
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small mole...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$771.10M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.95
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-112.17%
Volume
Today's trading volume
1.39M
Recent News
Lexicon Pharma (LXRX), Novo Nordisk (NVO) Initiate Phase 1 Study for Obesity Drug LX9851
Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) is one of the best biotech penny stocks to buy in 2026. On March 23, Lexicon Pharmaceuticals and Novo Nordisk (NYSE:NVO) initiated a Phase 1 clinical study for LX9851, a first-in-class, oral non-incretin small molecule inhibitor targeting obesity and metabolic disorders. Discovered by Lexicon and now under exclusive worldwide development by […]
How The Lexicon Pharmaceuticals (LXRX) Investment Story Is Shifting With Pilavapadin And LX9851
Lexicon Pharmaceuticals is back in focus as Street price targets now cluster in a wider band, roughly between US$2.30 and US$6.00 per share. This shift lines up with more constructive analyst commentary around the pilavapadin program, including a higher 30% success probability and the prospect of an "important partnership" on the Phase 3 ready asset. Read on to see how these updated views can help you track the evolving Lexicon story and decide how closely you want to follow it. Analyst Price...
Lexicon Pharmaceuticals (LXRX) to Present Phase 2b Pilavapadin Data
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is one of the 10 Best Penny Stocks to Buy and Hold Under $5. On April 16, 2026, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced that results from its PROGRESS Phase 2b study of pilavapadin in diabetic peripheral neuropathic pain (DPNP) will be presented on April 22 at the American Academy of Neurology Annual […]
How The Lexicon Pharmaceuticals (LXRX) Story Is Shifting Around Pilavapadin And Valuation Assumptions
The fair value estimate for Lexicon Pharmaceuticals sits at US$3.36, with recent price target moves on the Street leaning on how analysts now frame pilavapadin and the broader risk profile of the pipeline. Higher targets are being linked to a 30% assumed probability of success for pilavapadin and expectations around a potential partnership, while more cautious voices point to execution and deal uncertainty that could challenge those assumptions. As you read on, you will see how to track these...
LXRX Stock Up as NVO Initiates Phase I Study of Partnered Obesity Drug
Lexicon Pharmaceuticals stock jumps as NVO launches phase I study of oral obesity candidate LX9851, advancing a promising partnered therapy.